A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trialMichael Boyle, David M. Rodman, Michael W. Konstan et al.|The Lancet Respiratory Medicine|2014Cited by 442